3 January 2023 in Hepatology
Background and Aims: Overnutrition-induced activation of mammalian target of rapamycin (mTOR) dysregulates intracellular lipid metabolism and contributes to hepatic lipid deposition. Apolipoprotein J (ApoJ) is a molecular chaperone and participates in pathogen-induced and nutrient-induced lipid accumulation. This study investigates the mechanism of ApoJ-regulated ubiquitin-proteasomal degradation of mTOR, and a proof-of-concept ApoJ antagonist peptide is proposed to relieve hepatic steatosis. Approach and Results: By using omics approaches, upregulation of ApoJ was found in high-fat medium-fed hepatocytes and livers of patients with NAFLD. Hepatic ApoJ level associated with the levels of mTOR and protein markers of autophagy and correlated positively with lipid contents in the liver of mice. Functionally, nonsecreted intracellular ApoJ bound to mTOR kinase domain and prevented mTOR ubiquitination by interfering FBW7 ubiquitin ligase interaction through its R324 residue. In vitro and in vivo gain-of-function or loss-of-function analysis further demonstrated that targeting ApoJ promotes proteasomal degradation of mTOR, restores lipophagy and lysosomal activity, thus prevents hepatic lipid deposition. Moreover, an antagonist peptide with a dissociation constant (Kd) of 2.54 µM interacted with stress-induced ApoJ and improved hepatic pathology, serum lipid and glucose homeostasis, and insulin sensitivity in mice with NAFLD or type II diabetes mellitus. Conclusions: ApoJ antagonist peptide might be a potential therapeutic against lipid-associated metabolic disorders through restoring mTOR and FBW7 interaction and facilitating ubiquitin-proteasomal degradation of mTOR.
20 June 2025 in Cellular and Molecular Gastroenterology and Hepatology
Dysregulation of the STAT3 signaling pathway is closely linked to redox homeostasis and exacerbates liver injury. Apolipoprotein J (ApoJ), a chaperone sensitive to redox changes. We aim to investigate how hepatocyte ApoJ regulates the STAT3 pathway to mediate paracrine signaling that activates hepatic stellate cells (HSCs). We constructed ApoJ hepatocyte-specific knockout (ApoJ HKO) and overexpression mouse models and induced experimental liver fibrosis. The intercellular signaling between hepatocytes and HSCs was studied by treating HSCs with hepatocyte culture supernatants. Additionally, single-cell RNA sequencing datasets from patients with liver cirrhosis and healthy controls were analyzed. ApoJ levels in hepatocytes were significantly increased in patients with liver cirrhosis and in several liver fibrosis mouse models. Single-cell RNA analysis revealed that the upregulation of ApoJ primarily occurred in hepatocytes in liver fibrosis subject. ApoJ HKO significantly mitigated liver injury fibrosis models, characterized by reduced HSC activation, F4/80 macrophage infiltration, and maintain redox homeostasis. Conversely, hepatic overexpression of ApoJ aggravated the liver fibrosis phenotype. The underlying mechanism involves oxidative stress-induced ApoJ expression, which in turn enhances SUMOylation of STAT3 in K679 site through interaction with RanBP2. SUMOylation of STAT3 promotes its nuclear translocation, thereby activating the STAT3 pathway, and leads to an increase in TGF-β expression and ROS production in hepatocytes. Administration of the STAT3 inhibitor stattic effectively attenuated the progression of liver fibrosis in mice with hepatic ApoJ overexpression. ApoJ plays a pivotal role in accelerating the progression of liver fibrosis. Therapeutic strategies targeting the ApoJ/STAT3/RanBP2 axis may offer a novel approach for the prevention and treatment of fibrotic liver diseases.
17 July 2026 in Diabetologia